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Letters to the Editor 1223(interquartile range: 2.9% to 39%, p  0.001). Initial per-segment
LGE was associated with subsequent increases (r2 0.54, p 0.001).
The evolution of fibrosis is a dynamic process. Here, fibrosis
ither developed de novo, or increased over time. LGE appears to
ark a turning point, signposting a switch from increasing to
ecreasing wall thickness, and was associated with adverse remod-
ling and progressive disease. LGE represents focal myocardial
brosis. Both histological and biomarker studies suggest this is a
eterminant of LV diastolic properties and is associated with
oronary reserve, ischemia, arrhythmogenicity, and progression to
eart failure and sudden death (2). Over 7 years, de novo LGE
reas were observed, whereas established areas enlarged with
egmental thinning. LGE development was strongly predicted by
aseline LGE. This is not unexpected because fibrosis is a final
ommon pathway. However, the strength of the association raises
he possibility that focal fibrosis induces further fibrosis, supporting
he hypothesis that fibrosis may be a potential target in HCM using
ntifibrotic drugs (e.g., aldosterone antagonists) (5). The principal
imitation of this study is the high loss to follow-up: tracking
atients over 7 years was complex, particularly in this high-risk subset
f a tertiary referral HCM cohort with high rates of device implantation,
eath, or transplantation. Similarly, this cohort is unlikely to reflect a
ommunity-based HCM population.
In conclusion, over 7 years, in this cohort, HCM scar increased.
aseline CMR LGE predicted adverse remodeling, and the pres-
nce of LGE appears to represent a transition from increasing
ypertrophy to thinning. Scar begets scar, baseline CMR LGE
redicts future increases in CMR LGE.
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How Should Infarct Size be
Measured on LGE Sequences?
A Call for a Change in the Guidelines
In the February 2011 issue of iJACC, we read with great interest the
article by Flett et al. (1), in which the authors compared the
reproducibility of 7 late gadolinium enhancement (LGE) quantifi-
cation techniques across 3 clinical conditions. We noted that the
authors cite in their introduction and conclusion that the 2-SD
method as a threshold for LGE is a guideline-driven recommendation
set forth by Kramer et al. (2).
However, the reference to Kramer et al. (2) does not cover this
threshold of 2-SD assessment. We did find a 2009 guideline paper
by the Society for Cardiovascular Magnetic Resonance (3) that
recommended using “more than 2SD” as a cutoff to report scar area
on LGE. Note, however, that those guidelines (3) do not specifi-
cally address 2-SD as the best method for semiautomatic scar
measurement and do not specifically assess other thresholds or
threshold methods. We think this is highly relevant because in our
experience, and that of other investigators, higher thresholds (4) or
alternative (5) methods have been recommended.
This paper is very well done and points out the need for
guideline-based assessment to standardize methods for quantitative
LGE assessment given its increasing importance in clinical and
research studies.
Marcelo Souto Nacif, MD, PhD, Atul R. Chugh, MD,
João A. C. Lima, MD, MBA, David A. Bluemke, MD, PhD*
*National Institutes of Health, Radiology and Imaging Sciences, 10
Center Drive, Bldg 10/1C355, Bethesda, Maryland 20892. E-mail:
bluemked@cc.nih.gov
doi:10.1016/j.jcmg.2011.08.010
R E F E R E N C E S
1. Flett AS, Hasleton J, Cook C, et al. Evaluation of techniques for the
quantification of myocardial scar of differing etiology using cardiac
magnetic resonance. J Am Coll Cardiol Img 2011;4:150–6.
2. Kramer CM, Barkhausen J, Flamm SD, Kim RJ, Nagel E. Standardized
cardiovascular magnetic resonance imaging (CMR) protocols, Society for
Cardiovascular Magnetic Resonance: Board of Trustees Task Force on
Standardized Protocols. J Cardiovasc Magn Reson 2008;10:35.
3. Hundley WG, Bluemke D, Bogaert JG, et al. Society for Cardiovascular
Magnetic Resonance guidelines for reporting cardiovascular magnetic
resonance examinations. J Cardiovasc Magn Reson 2009;11:5.
4. Bondarenko O, Beek AM, Hofman MB, et al. Standardizing the
definition of hyperenhancement in the quantitative assessment of infarct
size and myocardial viability using delayed contrast-enhanced CMR.
J Cardiovasc Magn Reson 2005;7:481–5.
5. Amado LC, Gerber BL, Gupta SN, et al. Accurate and objective infarct
sizing by contrast-enhanced magnetic resonance imaging in a canine
myocardial infarction model. J Am Coll Cardiol 2004;44:2383–9.
